BiomeBank Appoints Ex-Ellerston Capital CIO and BlackRock North Asia Director as Chair to Accelerate Commercialisation Strategy

2022-01-20 11:47

Already collect

BiomeBank Appoints Ex-Ellerston Capital CIO and BlackRock North Asia Director as Chair to Accelerate Commercialisation Strategy

AsiaNet 94126

ADELAIDE, Jan. 20/Medianet International-AsiaNet/--
- BiomeBank appoints Mr Chris Hall as Chair, effective 17 January 2022.
- Mr Hall brings over 30 years' experience and impressive track record of 
investment management across both public and private markets within APAC. 
- BiomeBank's Series A funding round anticipated to close in early 2022.  
- Formal Therapeutic Goods Association ("TGA") approval of Company's 
first-generation microbial therapy anticipated in 2022. 
BiomeBank today announces Mr Chris Hall as the new Chair for the clinical stage 
biotechnology company, having recently served as Chief Investment Officer of 
Ellerston Capital. Prior to this, Mr Hall served as Managing Director of 
BlackRock Asset Management (North-Asia Ltd). The appointment is effective as of 17 January 2022.
Mr Hall succeeds Dr Stephen Rodda, who recently retired having served as the 
BiomeBank Chair since 2019.
BiomeBank Chief Executive Officer, Mr Thomas Mitchell said: "We're thrilled to 
welcome Mr Hall as the new Chair of BiomeBank. He brings with him over 30 
years' experience and an impressive track record of investment management 
across both public and private markets within the APAC region. 
"As we move towards closing our Series A funding round in early 2022 and formal 
TGA approval of our first-generation product, Mr Hall's experience in global 
markets will support our growth ambition into the Asia Pacific and European 
region. He also brings strong expertise in governance, holding a number of 
previous and current Board positions including Chair of the ESG Committee at 
Ellerston Capital, Chair of Perks Private Wealth and Non-Executive Director of 
Funds SA."
BiomeBank Chief Medical Officer and co-founder, Dr Sam Costello added: "I'd 
like to acknowledge and thank Dr Rodda for his dedication and support of the 
Company during its early stages of development and his role in the CEO 
recruitment. His expertise in commercialisation and building start-up and 
scale-up companies was an important driver of the business during this time."
The newly elected BiomeBank Chair, Mr Chris Hall said: "I'm excited to join 
BiomeBank as we move into the next stage of expansion and progress our 
promising pipeline of second-generation products.
"Having observed the Company's expertise in developing microbial therapies to 
treat unmet need, I believe we're in a strong position to improve the quality 
of life for people and continue to build our business into a global 
biotechnology leader.
"I'd like to acknowledge Dr Rodda for laying the foundations for the Company's 
early growth. I'm delighted to be working alongside such an experienced Board 
and Executive team at BiomeBank, as we deliver on our development pipeline, 
commercialise new therapies and increase shareholder value."
About BiomeBank 
BiomeBank is a clinical stage biotechnology company developing a pipeline of 
microbiome therapies to treat unmet medical need. BiomeBank's mission is to 
treat and prevent disease by restoring gut microbial ecology. 
Backed by a world-leading team of translational microbiome experts, BiomeBank's 
platform uses a unique combination of machine learning and microbiology to 
identify bacterial strains which influence disease, leading to the discovery 
and development of new therapies.
SOURCE: BiomeBank  
Related News
Add comments

Latest comments

Latest News
News Most Viewed